Moomoo AI 已提取核心信息
180 Life Sciences Corp. has announced the completion of a reverse stock split of its common stock, which was effective on February 28, 2024. The reverse stock split was executed at a ratio of 1-for-19, consolidating every nineteen shares of issued and outstanding common stock into one share. This action was taken to comply with the NASDAQ's minimum bid price requirement for continued listing on the NASDAQ Capital Market. The company's common stock began trading on a post-split basis on February 28, 2024, under the unchanged trading symbols 'ATNF' for common stock and 'ATNFW' for public warrants. The total number of outstanding shares was reduced from approximately 11.3 million to about 0.6 million. The reverse stock split was approved by stockholders on February 16, 2024, and...Show More
180 Life Sciences Corp. has announced the completion of a reverse stock split of its common stock, which was effective on February 28, 2024. The reverse stock split was executed at a ratio of 1-for-19, consolidating every nineteen shares of issued and outstanding common stock into one share. This action was taken to comply with the NASDAQ's minimum bid price requirement for continued listing on the NASDAQ Capital Market. The company's common stock began trading on a post-split basis on February 28, 2024, under the unchanged trading symbols 'ATNF' for common stock and 'ATNFW' for public warrants. The total number of outstanding shares was reduced from approximately 11.3 million to about 0.6 million. The reverse stock split was approved by stockholders on February 16, 2024, and the Board of Directors determined the ratio following the Special Meeting. No fractional shares were issued; instead, stockholders received rounded up whole shares. The reverse stock split did not affect the par value or the voting rights of the common stock. The company's transfer agent, Continental Stock Transfer & Trust Company, is providing instructions to stockholders regarding the reverse stock split. The move aims to increase the closing bid price of the company's common stock to satisfy NASDAQ's minimum bid price requirement, following a deficiency notice received from NASDAQ on September 7, 2023.
180 生命科学公司宣布完成其普通股的反向股票拆分,该拆分于2024年2月28日生效。反向股票拆分以1比19的比例执行,将每十九股已发行和流通普通股合并为一股。采取此项行动是为了遵守纳斯达克继续在纳斯达克资本市场上市的最低出价要求。该公司的普通股于2024年2月28日开始在拆分后的基础上交易,普通股的交易代码为 “ATNF”,公共认股权证的交易代码为 “ATNFW”。已发行股票总数从约1130万股减少到约60万股。股东于 2024 年 2 月 16 日批准了反向股票拆分,董事会在特别会议之后确定了该比例。没有发行零碎股票;相反,股东收到的股份是四舍五入。反向股票拆分并未影响普通股的面值或投票权。该公司的过户代理人大陆股票转让与信托公司正在向股东提供有关反向股票拆分的指示。在纳斯达克于2023年9月7日收到亏损通知后,此举旨在提高公司普通股的收盘出价,以满足纳斯达克的最低出价要求。
180 生命科学公司宣布完成其普通股的反向股票拆分,该拆分于2024年2月28日生效。反向股票拆分以1比19的比例执行,将每十九股已发行和流通普通股合并为一股。采取此项行动是为了遵守纳斯达克继续在纳斯达克资本市场上市的最低出价要求。该公司的普通股于2024年2月28日开始在拆分后的基础上交易,普通股的交易代码为 “ATNF”,公共认股权证的交易代码为 “ATNFW”。已发行股票总数从约1130万股减少到约60万股。股东于 2024 年 2 月 16 日批准了反向股票拆分,董事会在特别会议之后确定了该比例。没有发行零碎股票;相反,股东收到的股份是四舍五入。反向股票拆分并未影响普通股的面值或投票权。该公司的过户代理人大陆股票转让与信托公司正在向股东提供有关反向股票拆分的指示。在纳斯达克于2023年9月7日收到亏损通知后,此举旨在提高公司普通股的收盘出价,以满足纳斯达克的最低出价要求。
有用
没用